Assenagon Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $6.59M | Sell |
|
|||||
|
2025
Q2 | $7.57M | Sell |
|
|||||
|
2025
Q1 | $43.5M | Buy |
|
|||||
|
2024
Q4 | $3.57M | Sell |
|
|||||
|
2024
Q3 | $3.43M | Sell |
|
|||||
|
2024
Q2 | $34.3M | Sell |
|
|||||
|
2024
Q1 | $46.6M | Buy |
|
|||||
|
2023
Q4 | $41.6M | Sell |
|
|||||
|
2023
Q3 | $65.8M | Buy |
|
|||||
|
2023
Q2 | $25M | Buy |
|
|||||
|
2023
Q1 | $9.16M | Sell |
|
|||||
|
2022
Q4 | $24.9M | Buy |
|
|||||
|
2022
Q3 | $9.01M | Sell |
|
|||||
|
2022
Q2 | $13.6M | Buy |
|
|||||
|
2022
Q1 | $1.3M | Sell |
|
|||||
|
2021
Q4 | $7.31M | Buy |
|
|||||
|
2021
Q3 | $1.07M | Sell |
|
|||||
|
2021
Q2 | $4.78M | Buy |
|
|||||
|
2021
Q1 | $314K | Buy |
|
|||||
|
2020
Q3 | – | Sell |
|
|||||
|
2020
Q2 | $2.8M | Buy |
|
|||||
|
2019
Q4 | – | Sell |
|
|||||
|
2019
Q3 | $2.24M | Buy |
|